Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

1,847 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Randomized trial of cyclophosphamide, epirubicin, and fluorouracil chemotherapy compared with cyclophosphamide, methotrexate, and fluorouracil with node-positive breast cancer in Japan.
Kimura M, Tominaga T, Takatsuka Y, Toi M, Abe R, Koyama H, Takashima S, Nomura Y, Miura S, Kimijima I, Tashiro H, Ohashi Y; Adjuvant CEF Research Group for Breast Cancer. Kimura M, et al. Among authors: takashima s. Breast Cancer. 2010 Jul;17(3):190-8. doi: 10.1007/s12282-009-0132-x. Epub 2009 Jul 3. Breast Cancer. 2010. PMID: 19575284 Clinical Trial.
Effects of toremifene and tamoxifen on lipid profiles in post-menopausal patients with early breast cancer: interim results from a Japanese phase III trial.
Tominaga T, Kimijima I, Kimura M, Takatsuka Y, Takashima S, Nomura Y, Kasumi F, Yamaguchi A, Masuda N, Noguchi S, Eshima N. Tominaga T, et al. Among authors: takashima s. Jpn J Clin Oncol. 2010 Jul;40(7):627-33. doi: 10.1093/jjco/hyq021. Epub 2010 Apr 8. Jpn J Clin Oncol. 2010. PMID: 20382637 Clinical Trial.
[CGS20267 (Letrozole), a new aromatase inhibitor: late phase II study in postmenopausal women with advanced or recurrent breast cancer (no. 2)--evaluation of efficacy and safety at the recommended clinical dose CGS20267 Study Group].
Kimijima I, Tominaga T, Nomizu T, Nomura Y, Takashima S, Koyama H, Sano M, Tohge T, Ueo H, Ikeda S, Ohashi Y; CGS20267 Study Group. Kimijima I, et al. Among authors: takashima s. Gan To Kagaku Ryoho. 2002 May;29(5):741-9. Gan To Kagaku Ryoho. 2002. PMID: 12040678 Clinical Trial. Japanese.
[Early phase II dose-finding study of exemestane in postmenopausal patients with advanced/recurrent breast cancer].
Tabei T, Ogita M, Hirata K, Satomi S, Kimura M, Abe R, Morishita Y, Kimura M, Andou J, Higashi Y, Yoshino K, Tominaga K, Kajiwara T, Kitajima M, Koyanagi Y, Watanabe T, Yamaguchi S, Watanabe M, Toyama K, Kanda K, Kashiki Y, Miura S, Kobayashi Z, Aoyama H, Miyazaki I, Oka T, Koyama H, Kinoshita H, Monden M, Takai S, Yayoi E, Kobayashi T, Takatsuka Y, Kajiwara T, Sonoo H, Toge T, Takashima S, Nomura Y, Nagao K, Fujita Y. Tabei T, et al. Among authors: takashima s. Gan To Kagaku Ryoho. 2002 Jul;29(7):1199-209. Gan To Kagaku Ryoho. 2002. PMID: 12146001 Clinical Trial. Japanese.
1-hexylcarbamoyl-5-fluorouracil + cyclophosphamide + tamoxifen versus CMF + tamoxifen in women with lymph node-positive breast cancer after primary surgery: a randomized controlled trial.
Tominaga T, Kimura M, Asaga T, Yoshida M, Awane H, Koyama H, Takatsuka Y, Mitsuyama S, Ikeda T, Ogita M, Aoyama H, Sano M, Abe R, Nishi T, Wada T, Danno M, Toi M, Takashima S. Tominaga T, et al. Among authors: takashima s. Oncol Rep. 2004 Oct;12(4):797-803. Oncol Rep. 2004. PMID: 15375502 Clinical Trial.
A multicenter Phase II study evaluating the efficacy, safety and pharmacokinetics of trastuzumab emtansine in Japanese patients with heavily pretreated HER2-positive locally recurrent or metastatic breast cancer.
Kashiwaba M, Ito Y, Takao S, Doihara H, Rai Y, Kanatani K, Takashima S, Masuda N. Kashiwaba M, et al. Among authors: takashima s. Jpn J Clin Oncol. 2016 May;46(5):407-14. doi: 10.1093/jjco/hyw013. Epub 2016 Feb 24. Jpn J Clin Oncol. 2016. PMID: 26917603 Clinical Trial.
1,847 results